Shanghai Shengdi Pharmaceutical Co., Ltd clinical trials
A subsidiary of Jiangsu HengRui Medicine Co., Ltd.
The registry lists 9 studies whose lead sponsor is Shanghai Shengdi Pharmaceutical Co., Ltd. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 10, 2026.
Where
- China
- 9
Registry sponsor names on this page
- Shanghai Shengdi Pharmaceutical Co., Ltd9 studies
Something wrong with this grouping? Tell us on the Jiangsu HengRui Medicine Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Jiangsu HengRui Medicine Co., Ltd. studies →
- A Study of SHR-4610 Injection in Patients With Advanced Solid TumorsRecruitingNCT07231211Phase 1/2
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction CancerRecruitingNCT07522151Phase 3
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical CancerRecruitingNCT07168200Phase 3
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingNCT06335355Phase 2/3
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) LesionsCompletedNCT07275723Phase 3
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) LesionsCompletedNCT07275814Phase 3
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy SubjectsCompletedNCT07123376Phase 1
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal FunctionCompletedNCT06657560Phase 1
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd
- A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical CancerActive, not recruitingNCT06237257Phase 2
Sponsor listed in the registry: Shanghai Shengdi Pharmaceutical Co., Ltd